Advertisement
U.S. markets open in 3 hours 11 minutes

Axonics, Inc. (AXNX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
68.25+0.44 (+0.65%)
At close: 04:00PM EDT
67.85 -0.40 (-0.59%)
After hours: 06:13PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close67.81
Open67.75
Bid67.58 x 1000
Ask67.55 x 800
Day's Range67.75 - 68.29
52 Week Range47.59 - 69.68
Volume721,014
Avg. Volume1,274,943
Market Cap3.481B
Beta (5Y Monthly)0.56
PE Ratio (TTM)N/A
EPS (TTM)-0.12
Earnings DateApr 29, 2024 - May 03, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est71.73
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-46% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for AXNX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Axonics, Inc.
    Daily – Vickers Top Buyers & Sellers for 01/19/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • Business Wire

    Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System

    IRVINE, Calif., March 14, 2024--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the Axonics R20™ rechargeable sacral neuromodulation (SNM) system has received CE Mark approval.

  • Simply Wall St.

    Axonics Full Year 2023 Earnings: EPS Beats Expectations

    Axonics ( NASDAQ:AXNX ) Full Year 2023 Results Key Financial Results Revenue: US$366.4m (up 34% from FY 2022). Net...

  • Business Wire

    Axonics Responds to ITC Action by Medtronic

    IRVINE, Calif., February 29, 2024--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received notice that Medtronic has filed a complaint with the U.S. International Trade Commission (ITC), along with a parallel action in U.S. District Court for the District of Delaware. The complaint alleges that Axonics infringes two Medtronic patents that purportedly relate to a "patient programmer with automated MRI compatibility verification" for an implantable medical device.